Melanostatin
Title: Melanostatin
CAS Registry Number: 9083-38-9
Additional Names: Melanocyte-stimulating hormone release-inhibiting factor; MIF; MRIH; MSH release-inhibiting hormone; melanotropin inhibiting factor
Literature References: An inhibiting factor which mediates hypothalamic control of MSH, q.v., a pituitary hormone: A. J. Kastin, A. V. Schally, Gen. Comp. Endocrinol. 7, 452 (1966); A. V. Schally, A. J. Kastin, Endocrinology 79, 768 (1966). Although several substances have MIF activity, the exact nature of MSH release inhibition is not known, cf. A. J. Kastin et al., Yale J. Biol. Med. 46, 617 (1973); eidem, Fed. Proc. 39, 2931 (1980). The first factor with melanocyte-release inhibiting activity to be isolated was the side-chain tripeptide of oxytocin, q.v., now referred to as MIF-I: M. E. Celis et al., Proc. Natl. Acad. Sci. USA 68, 1428 (1971). Isoln of bovine MIF-I and identity with the tripeptide (Pro-Leu-GlyNH2): R. M. G. Nair et al., Biochem. Biophys. Res. Commun. 43, 1376 (1971). Synthesis: H. Irie et al., Chem. Lett. 1980, 705. Extrapituitary effects of MIF-I are known, particularly potentiation of DOPA-induced behavioral changes: N. P. Plotnikoff et al., Life Sci. 10, 1279 (1971); eidem, Neuroendocrinology 14, 271 (1974). Clinical studies in Parkinson's disease: A. J. Kastin, A. Barbeau, Can. Med. Assoc. J. 107, 1079 (1972); A. Barbeau, Lancet 2, 683 (1975); V. E. Schneider et al., Arzneim.-Forsch. 28, 1296 (1978). Reviews: A. V. Schally et al., Recent Prog. Horm. Res. 24, 497-581 (1968); A. J. Kastin et al., Life Sci. 25, 401-414 (1979); eidem in Polypeptide Hormones, R. F. Beers, E. G. Bassett, Eds. (Raven Press, New York, 1980) pp 223-224; eidem, Fed. Proc. 39, 2931-2936 (1980).
 
Derivative Type: MIF-I
CAS Registry Number: 2002-44-0
CAS Name: L-Prolyl-L-leucylglycinamide
Additional Names: melanostatin I (ox); MSH release-inhibiting factor I
Molecular Formula: C13H24N4O3
Molecular Weight: 284.35
Percent Composition: C 54.91%, H 8.51%, N 19.70%, O 16.88%

Others monographs:
allo-YohimbineThionyl ChlorideIridium TrichlorideGliclazide
2,4-Dinitrobenzenesulfenyl ChlorideMatén-Amyl BromideBeryllium Iodide
AcetarsonePlatinic IodideCyanamidePotassium Arsenate
LynestrenolEthyl PhenylacetateRioprostilNadolol
©2016 DrugLead US FDA&EMEA